Vilya
Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology. Their platform leverages advanced computational approaches to design new molecular structures, aiming to transform medicine creation, make high throughput screening obsolete, and ultimately cure disease. Founded by scientists from the Institute of Protein Design led by David Baker, Ph.D., and ARCH Venture Partners, Vilya focuses on designing chemically diverse macrocycles for disease targeting.
Industries
Nr. of Employees
small (1-50)
Products
Novel class of medicines
Vilya develops medicines that target disease biology with precision, using computational biotechnology.
Computational platform for drug design
The company uses advanced computational approaches to design new molecular structures for drug development.
Novel class of medicines
Vilya develops medicines that target disease biology with precision, using computational biotechnology.
Computational platform for drug design
The company uses advanced computational approaches to design new molecular structures for drug development.
Services
Computational molecular design platform
Proprietary computational platform and internal research programs for de novo design of chemically diverse macrocycles and cyclic peptides aimed at therapeutic applications.
Computational molecular design platform
Proprietary computational platform and internal research programs for de novo design of chemically diverse macrocycles and cyclic peptides aimed at therapeutic applications.
Expertise Areas
- Computational drug design
- Macrocycle and cyclic peptide therapeutics
- Machine learning for molecular design
- Molecular modeling and computational chemistry
Key Technologies
- De novo macrocycle design
- Machine learning-driven design
- Structure prediction for peptides
- Computational protein/peptide design